Royal Prima PT (PRIM) - Total Liabilities

Latest as of September 2025: Rp111.14 Billion IDR ≈ $6.51 Million USD

Based on the latest financial reports, Royal Prima PT (PRIM) has total liabilities worth Rp111.14 Billion IDR (≈ $6.51 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Royal Prima PT (PRIM) cash conversion ratio to assess how effectively this company generates cash.

Royal Prima PT - Total Liabilities Trend (2014–2024)

This chart illustrates how Royal Prima PT's total liabilities have evolved over time, based on quarterly financial data. Check PRIM asset liquidity ratio to evaluate the company's liquid asset resilience ratio.

Royal Prima PT Competitors by Total Liabilities

The table below lists competitors of Royal Prima PT ranked by their total liabilities.

Company Country Total Liabilities
Genenta Science SpA ADR
NASDAQ:GNTA
USA $9.44 Million
Enzo Biochem Inc
NYSE:ENZ
USA $20.12 Million
Pineapple Financial Inc.
NYSE MKT:PAPL
USA $16.12 Million
Tasman Resources Ltd
AU:TAS
Australia AU$227.26K
Indbank Merchant Banking Services Limited
NSE:INDBANK
India Rs212.35 Million
ViroGates A/S
CO:VIRO
Denmark Dkr11.38 Million
Maheshwari Logistics Limited
NSE:MAHESHWARI
India Rs4.41 Billion

Liability Composition Analysis (2014–2024)

This chart breaks down Royal Prima PT's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see PRIM market cap.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.77 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio 0.05 Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.12 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.10 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Royal Prima PT's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Royal Prima PT (2014–2024)

The table below shows the annual total liabilities of Royal Prima PT from 2014 to 2024.

Year Total Liabilities Change
2024-12-31 Rp122.17 Billion
≈ $7.16 Million
+145.89%
2023-12-31 Rp49.69 Billion
≈ $2.91 Million
-4.20%
2022-12-31 Rp51.86 Billion
≈ $3.04 Million
-68.97%
2021-12-31 Rp167.11 Billion
≈ $9.79 Million
+174.17%
2020-12-31 Rp60.95 Billion
≈ $3.57 Million
+0.95%
2019-12-31 Rp60.38 Billion
≈ $3.54 Million
-4.81%
2018-12-31 Rp63.43 Billion
≈ $3.72 Million
+7.11%
2017-12-31 Rp59.22 Billion
≈ $3.47 Million
+126.60%
2016-12-31 Rp26.13 Billion
≈ $1.53 Million
-0.95%
2015-12-31 Rp26.38 Billion
≈ $1.55 Million
+89.58%
2014-12-31 Rp13.92 Billion
≈ $815.50K
--

About Royal Prima PT

JK:PRIM Indonesia Medical Care Facilities
Market Cap
$16.43 Million
Rp280.40 Billion IDR
Market Cap Rank
#25610 Global
#570 in Indonesia
Share Price
Rp83.00
Change (1 day)
-3.49%
52-Week Range
Rp57.00 - Rp102.00
All Time High
Rp1640.00
About

PT Royal Prima Tbk engages in providing hospital services in Indonesia. The company operates its hospitals under the Royal Prima Medan, Royal Prima Jambi, and RSU Royal Prima Marelan names. It provides health services, such as emergency, outpatient, inpatient, laboratorium, radiology, medical rehab, pharmacy, and MCU; and general surgery, internist, VCT, ICU, cardiology, urology, haemodialysis, m… Read more